UroDapter®



Company:

UroSystem

At UroSystem, our mission is to provide practice changing medical solutions for urinary bladder diseases to patients and health practitioners by facilitating timely diagnosis, effective treatment, and life-long follow-up.

Contact:

Mail@urosystem.com

 $Uro System\,Zrt.$

Szent Istvan park 26. fszt. 2.

1137 Budapest

Hungary

www.urosystem.com


www.urodapter.com

Product:

The UroDapter®

During intravesical instillation therapies catheterization can cause serious side effects or complications. It is usually painful and raises the risk of infections. These factors often discourage both therapists and patients from opting for this treatment method even when it is the most effective option.

The UroDapter®, a groundbreaking invention, has been designed to overcome these issues. It is an innovative urological syringe adapter for catheter-free intravesical instillations specifically engineered for optimal efficiency and patient comfort. It can be used in both male and female patients.



Benefits of the UroDapter® include:



Painless Alternative: Provides a painless and effective alternative to conventional catheterization.




Versatile Treatment: Suitable for a wide range of bladder indications that require instillation. (Not suitable for draining purposes.)



Therapist-Friendly: Easy to learn and use, allowing therapists to achieve optimal results.



Treating the Urethra, too: The UroDapter® makes it easy to treat the bladder ad urethra simultaneously



The UroDapter® is particularly beneficial in the treatment of the following indications in both sexes:

- 1. Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- 2. Recurrent Urinary Tract Infection (rUTIs)
- 3. Complications of Oncotherapy: Radiation-Induced Cystitis and Chemotherapy-induced Cystitis
- 4. Lidocaine Administration as a local a nesthetic in several indications
- 5. Other indications of emerging intravesical treatment modalities: Overactive Bladder (OAB), acute treatment of hard-to-treat UTIs, Neural Therapy

The above indications are well-defined target audience due to their need for regular, often life-long treatments. It is essential to assess the presence of practitioners specializing in the respective indications, the level of awareness of the indications, and current treatment methods within the local market.

For successful market launch, a gradual and focused approach is advised:

- Target early adopters, patients, and clinics to build usage and awareness.
- Provide comprehensive training materials, tutorials, and training sessions.
- Offer follow-up support and step-by-step expansion to ensure proper adoption.
- Avoid mass sales without a dequate training and support.

The UroDapter® is a class 1 medical device in Europe and the U.S. It is a single-use device, comes in sterile packaging. Its CE mark under MDD was obtained (and so shall happen under MDR soon). It is registered by the FDA (Food and Drug Administration) in the USA. The UroDapter® has been sold in 20 countries, primarily in Europe, under the name of i Aluadapter®.

References:

1. Minimally invasive device for intravesical instillation by urological syringe adapter (MID-ii U. S. A.) for catheter-free instillation therapy of the bladder in interstitial cystitis/bladder pain syndrome.

Lovasz S, *Int J Urol* **26** (suppl 1):57-60. (2019) https://doi.org/10.1111/iju.13976 2. Ialuadapter in der Praxis. (German) Unger-Hunt, *J. Urol. Urogynäkol. AT* **26**, 103 (2019). https://doi.org/10.1007/s41972-019-00079-1

3. Instillation frei von Katheter. (German) Unger-Hunt, *Urol. Prax.* **21**, 166 (2019). https://doi.org/10.1007/s41973-019-00081-y We stand strongly with our values:

- Clinical quality
- Empathy
- Integrity
- Passion
- Scientific excellence